Patients that had metastatic disease before or at sample acquisition had significantly lower galectin-1 levels than those without metastatic disease (p = 0.0344), but there was no significant difference for galectin-3 (p = 0.1039) or galectin-9 (p = 0.0582), as seen in Figure 4. Here, LGALS9 is linked to metastatic neoplasm.